Medical Health & Life Science Research News

Acute respiratory distress syndrome - market forecast, H1 2017 scrutinized in new research

Acute respiratory distress syndrome - market forecast, H1 2017 scrutinized in new research

Mentioning Key Players Altor BioScience Corp, Athersys Inc, Commence Bio Inc

- Advertisement -
- Membership expired -

Summary
Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Request a sample report @ www.htfmarketreport.com/sample-rep…e-pipeline-review

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

- Advertisement -
- Membership expired -
Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=280868

Reasons to access


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Enquire for Discount @ www.htfmarketreport.com/request-di…e-pipeline-review

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Altor BioScience Corp
Athersys Inc
Commence Bio Inc
Faron Pharmaceuticals Oy
GlaxoSmithKline Plc
Global Blood Therapeutics Inc
Hydra Biosciences Inc
Implicit Bioscience Ltd
Phylogica Ltd
Savara Inc
Silence Therapeutics Plc
Acute Respiratory Distress Syndrome - Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-11006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBT-440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
……………………….. Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/28…e-pipeline-review

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…e-pipeline-review
  • www.htfmarketreport.com/buy-now?fo…amp;report=280868
  • www.htfmarketreport.com/request-di…e-pipeline-review
  • www.htfmarketreport.com/reports/28…e-pipeline-review